|
16 Sep 2025 |
Glenmark Pharma
|
Consensus Share Price Target
|
2099.50 |
2248.67 |
- |
7.11 |
buy
|
|
|
|
|
29 Jan 2016
|
Glenmark Pharma
|
ICICI Securities Limited
|
2099.50
|
975.00
|
771.35
(172.19%)
|
Target met |
Buy
|
|
|
|
|
02 Jan 2016
|
Glenmark Pharma
|
Karvy
|
2099.50
|
1116.00
|
923.75
(127.28%)
|
|
Buy
|
|
|
US-Big opportunities ahead: USFDA approval for Glenmark generics hasslowed from 18 in FY11 to 6 in FY15 even as 37 plain filings are pending forapproval for Glenmark. The improved approval rate (8 in H1-FY16) should sustain regular growth while incrementally gZetia (with 180 day exclusivity), gZyvox and gVoricanozole should support an 18% CAGR US formulations growth in FY15-18E.
|
|
30 Oct 2015
|
Glenmark Pharma
|
Phillip Capital
|
2099.50
|
1090.00
|
991.50
(111.75%)
|
|
Neutral
|
|
|
9 US sales saw steady yoy growth of 10% despite 57% price erosion in base portfolio; GNPguidesforstrongH2ledbypickupinrecent/newlaunches Domesticformulationswereaheadofexpectationswith27%yoyimprovementdueto...
|
|
30 Oct 2015
|
Glenmark Pharma
|
Reliance Securities
|
2099.50
|
1160.00
|
991.00
(111.86%)
|
|
Buy
|
|
|
ff Management expects slowdown in Venezuela as it is hard to obtain the requisite import license. Potential threat of significant devaluation in Venezuela puts US$2030mn of company's exposure there at risk. As per our estimates, Venezuela contributed ~6% of FY15 profits. Factoring in the devaluation in FY17E, we...
|
|
03 Aug 2015
|
Glenmark Pharma
|
Phillip Capital
|
2099.50
|
940.00
|
989.75
(112.12%)
|
|
Neutral
|
|
|
company maintained its sales growth guidance of 1820% and EBITDA of ~Rs 17.5bn (implying ~22% margin) on a presumed ramp up in US generic sales and continued momentum in domestic formulations. However, modest US sales growth (8.5%) in Q1...
|
|
03 Jun 2015
|
Glenmark Pharma
|
Phillip Capital
|
2099.50
|
975.00
|
853.80
(145.90%)
|
Target met |
Buy
|
|
|
broadbased improvement in US sales (20%), domestic formulations (1719%), and in EuropeandROWmarkets.IttargetsanEBITDAofRs17.5bn,implyingamarginof~22% (lower than our estimate of 22.7%) and tax incidence of 2324% (we factored 22%). The...
|
|
22 Apr 2014
|
Glenmark Pharma
|
Reliance Securities
|
2099.50
|
709.00
|
574.50
(265.45%)
|
Target met |
Buy
|
|
|
Background: Tarka is a hypertension drug with market size of US$70mn. Glenmark had launched the drug "at-risk" in June 2010. However, the Federal Jury ruled against Glenmark in January 2011 and awarded Abbott US$16mn in...
|
|
27 Sep 2013
|
Glenmark Pharma
|
Ashika Research
|
2099.50
|
610.00
|
522.85
(301.55%)
|
Target met |
Buy
|
|
|
Glenmark pharma's (GNP) Q1FY14 revenues grew 19% YoY to Rs. 1238.2 cr driven by 33% growth in Latin America (specialty business), 25% growth in RoW markets, 26% growth in API...
|
|
15 May 2012
|
Glenmark Pharma
|
Ashika Research
|
2099.50
|
410.00
|
365.35
(474.65%)
|
Target met |
Buy
|
|
|
Glenmark Pharmaceuticals Ltd(GPL) is a research driven, integrated pharma company that has presence in both Generic and API business. The company is a leading player in the discovery of new molecules both new chemical...
|